Pages Menu
TwitterRssFacebook
ISSN (Online): 2454-1680

OncoExpert

INTERNATIONAL JOURNAL OF INTEGRATED ONCOLOGY

An Official Publication Of Society Of Pharmaceutical Science & Research
Categories Menu

Most Cited

 
Title
Views
PDF
Cited
5.

UNUSUAL PRESENTATION OF NON-HODGKIN LYMPHOMA: VULVA GROWTH AND BREAST MASS IN THE SAME PATIENT

Primary involvement of vulva or breast by non-hodgkin lymphoma (NHL) is known to occur uncommonly. Only 24 cases of NHL vulva and around 250 cases of NHL breast alone have been reported, so far; but none with simultaneous involvement of the two sites together. We report the first case having both sites involved in a 35 year old Indian female.

Yashpal Verma, Ashok K. Chauhan, Ramesh Sabharwal and Jagjeet Singh

Dr. Yashpal Verma, Medical Officer, Department of Radiotherapy, University of Health Sciences, Rohtak (INDIA). Contact no. +91-9416125026

DOI:

31-34

1764

871

0

4.

PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF BONE: MANAGING THE MISCELLANEOUS!

Anaplastic large cell lymphoma (ALCL) represents 2 to 3% of non-Hodgkin lymphoma (NHL). Anaplastic lymphoma kinase negative (ALK-) subtype accounts for 15-50% of all ALCL. Primary bone involvement in lymphoma is uncommon and constitutes less than 1% of all lymphomas and 4-5% of all extranodal NHL. Hence extra-nodal primary bone involvement in ALCL is even rarer. We report the 14th case of primary ALCL in a 38 year old Indian female. Other than the uncommon site, there is no reason not to keep NHL as differential diagnosis, as the condition responds too well to standard...

Sulbha Mittal, Yashpal Verma, Ashok K. Chauhan, Paramjeet Kaur, Anil Khurana, Nupur Bansal

Medical Officer, Department of Radiotherapy, University of Health Sciences, Rohtak (INDIA)

DOI:

25-29

1510

894

0

1.

ASTROBLASTOMA: DOES IT REQUIRE DIFFERENT TREATMENT ?

Background- Astroblastoma is partially understood, poorly reported and rare in occurrence tumor with significant dilemma regarding cellular origin, diagnostic criteria, clinical behavior, and management protocol. Material and method– Thorough search of published English scientific literature was made with search word Astroblastoma through Google Search, PubMed, Research Gate and Cochrane Library till June 2018. The reports thus collected were examined for data regarding age, gender, location and laterality of disease, pathological grade, treatment received, and outcome of treatment. Results– Data of 161 patients was retrieved from 72 publications. Median age at presentation was 18 years. Females were affected much more frequently than males. Most common site of involvement was the frontal lobe. Laterality data was inconsistent and sparingly reported. Most common presenting complaint was headache followed by history of seizure. Surgery was performed in majority of patients-79.6% of the patients underwent a gross total resection, 45% (44 out of 98 reported) had a high-grade tumor. Sixty patients received adjuvant radiation with a median dose of 54 Gy (Range 20-72), mostly for high grade, residual or recurrent disease. Adjuvant chemotherapy was used in 25 patients. Median follow-up was 43 months (range 1-238). Median overall survival was 138 months. Patients with a higher-grade tumor had significantly worse overall survival. Conclusion- Astroblastoma is rare but known to have two distinct grades, with higher-grade tumors bearing significantly poor survival. Maximal safe surgery is the standard. Though there is lack of consensus, adjuvant radiotherapy with or without Temozolamide should be considered in view of high rates of local...

Dr. Yashpal Verma

Additional Senior Medical Officer, Department of Radiation Oncology, PGIMS, Rohtak (India)

DOI:

01-09

377

126

0

1.

CANCER CHRONOTHERAPY: THE RIGHT TIME TO HIT!

Chronomodulated therapy or chronotherapy has gained popularity, beyond a fancy term, as a novel and logical method to exploit the best, by administering anti-cancer treatment at an optimal timing according to circadian rhythms of their anti-cancer action and/or repair mechanism of cancer & normal cells. Understanding of chronobiology and the results of clinical studies back up this new concept. Chronotherapy seems to have all the potential to become tomorrow’s accepted, refined oncology practice without adding much to the cost of existing...

Ashok Kumar Chauhan, Yashpal Verma and Ramesh Sabharwal

Dr Yashpal Verma, Medical Officer, Department of Radiotherapy, Post graduate institute of medical sciences, Rohtak (INDIA)

DOI:

1-7

2024

1033

0

3.

CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: METHODS TO MEASURE

Peripheral neuropathy is a structural or functional abnormality of peripheral nerves giving rise to neuropathic symptoms. Neuropathic symptoms can be motor, sensory and autonomic or varied combination of these major categories. Chemotherapeutic agents frequently cause various neuropathic symptoms and signs depending upon culprit agent, its dose and duration. Chemotherapy-Induced Peripheral Neurotoxicity is a common, disabling and dose-limiting side-effect of cancer treatment and its assessment is difficult. Some patients complain of tingling, numbness and pain in distal extremities while others may also develop motor and autonomic symptoms. Some patients remain symptomatic even after discontinuation of offending drugs. Patients with chemotherapy induced neuropathy bear higher healthcare cost than cancer patients without neuropathy. As new chemotherapeutic agents are being developed it is important to measure chemotherapy induced peripheral neuropathy accurately so that it can be recognized at an earlier stage, the treatment can be modified appropriately and disease progression can be monitored. An added advantage would be a possibility of reliable comparison between neuropathic side effect of newer and older chemotherapeutic...

Ravi Uniyal

Senior Resident, Department of Neurology, SGPGI, Lucknow, INDIA

DOI:

15-23

1621

0

0

Page 3 of 3123